Expert Interview
Discussing the potential of Syndax Pharmaceuticals' axatilimab with chronic GVHD and the results from the AGAVE-201 trial presented at ASH.
Ticker(s): SNDXInstitution: Dana Farber Cancer Institute
- Professor of Medicine, Harvard Medical School & Chief Emeritus of the Stem Cell Transplant Program of the Dana-Farber/Brigham and Women's Cancer Center.
- Treats 30 - 40 patients with cGVHD per year and 30 patients with Paroxysmal Nocturnal Hemoglobinuria each month.
- Research focuses on Graft-Versus-Host Disease and Graft-Versus-Leukemia Effect, aplastic anemia, and PNH.
Can you discuss the current treatment landscape for cGVHD?
Added By: sara_adminWhat are your thoughts on the poster and data presented at ASH from the AGAVE-201 trial?
Added By: sara_adminOn a scale from 1 to 10 how would you rate your level of excitement for axatilimab for your patients with cGVHD?
Added By: sara_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
